



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: 7 : C07D 23/94, 215/54, A61K 31/517, 31/4706, A61P 35/00, C07F 9/40, C07D 401/12, 493/12, 403/12, 405/12, 413/12		A1	(11) International Publication Number: WO 00/51991 (43) International Publication Date: 8 September 2000 (08.09.00)		
(21) International Application Number: PCT/EP00/01496		(74) Agent: LAUDIEN, Dieter; Boehringer Ingelheim GmbH, Corporate Patent Division, D-55216 Ingelheim/Rhein (DE).			
(22) International Filing Date: 24 February 2000 (24.02.00)		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).			
(71) Applicant (for all designated States except US): BOEHRINGER INGELHEIM PHARMA KG [DE/DE]; D-55216 Ingelheim/Rhein (DE).		(72) Inventors; and (73) Inventors/Applicants (for US only): HIMMELSBACH, Frank [DE/DE]; Ahornweg 16, D-88441 Mittelbiberach (DE), LANGKOPF, Elke [DE/DE]; Schloss 3, D-88447 Warthausen (DE), JUNG, Birgit [DE/DE]; Mühlstrasse 23, D-85270 Schwabheim (DE), METZ, Thomas [DE/AT]; Traungasse 6/5, A-1030 Vienna (AT), SOLCA, Flavio [CH/AT]; Fimbingergasse 19, A-1230 Vienna (AT), BLECH, Stefan [DE/DE]; Müllerweg 9, D-88447 Warthausen (DE).			
(54) Title: 4-AMINO-QUINAZOLINE AND QUINOLINE DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.			
(57) Abstract					
The present invention relates to bi-cyclic heterocycles of general formula (I), wherein $R_a$ to $R_d$ , A to G and X are defined as in claim 1, the tautomers, the stereoisomers and the salts thereof, particularly the physiologically acceptable salts thereof particularly the physiologically acceptable salts thereof with inor- ganic or organic acids or bases which have valuable pharmacological properties, particularly an inhibiting effect on signal transduction mediated by tyrosine kinases, their use for treating diseases, particularly tumoral diseases, diseases of the lungs and respiratory tract, and the preparation thereof.					
<p>Chemical structure of compound (I): A bi-cyclic heterocycle consisting of a quinoline ring fused to a quinazoline ring. The quinoline ring has substituents A, B, C, and D. The quinazoline ring has substituents E, F, and G. The fused ring junction is at position 4 of the quinoline ring and position 2 of the quinazoline ring. The fused ring junction is also bonded to an N-atom of the quinazoline ring. The N-atom is bonded to an R<sub>a</sub> group. The quinoline ring is bonded to an X-atom. The X-atom is bonded to an R<sub>b</sub> group. The quinazoline ring is bonded to an R<sub>c</sub> group. The quinazoline ring is bonded to an R<sub>d</sub> group.</p>					